Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Mind Medicine Inc’s stock clocked out at $8.39, down -1.18% from its previous closing price of $8.49. In other words, the price has decreased by -$1.18 from its previous closing price. On the day, 1.11 million shares were traded. MNMD stock price reached its highest trading level at $8.88 during the session, while it also had its lowest trading level at $8.18.
Ratios:
To gain a deeper understanding of MNMD’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.91 and its Current Ratio is at 3.91. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on May 29, 2024, initiated with a Outperform rating and assigned the stock a target price of $27.
On April 15, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $20.
On December 05, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $9.Canaccord Genuity initiated its Buy rating on December 05, 2023, with a $9 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 25 ’24 when Sullivan Mark sold 17,854 shares for $7.22 per share. The transaction valued at 128,906 led to the insider holds 182,146 shares of the business.
Barrow Robert sold 15,659 shares of MNMD for $113,058 on Jun 25 ’24. The Chief Executive Officer now owns 564,543 shares after completing the transaction at $7.22 per share. On Jun 25 ’24, another insider, Karlin Dan, who serves as the Chief Medical Officer of the company, sold 6,925 shares for $7.22 each. As a result, the insider received 49,998 and left with 351,527 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MNMD now has a Market Capitalization of 610197184 and an Enterprise Value of 364867616.
Stock Price History:
The Beta on a monthly basis for MNMD is 0.97, which has changed by 0.85209715 over the last 52 weeks, in comparison to a change of 0.23228896 over the same period for the S&P500. Over the past 52 weeks, MNMD has reached a high of $12.22, while it has fallen to a 52-week low of $2.41. The 50-Day Moving Average of the stock is 5.02%, while the 200-Day Moving Average is calculated to be 42.76%.
Shares Statistics:
It appears that MNMD traded 1.42M shares on average per day over the past three months and 1059827 shares per day over the past ten days. A total of 41.10M shares are outstanding, with a floating share count of 27.16M. Insiders hold about 3.54% of the company’s shares, while institutions hold 119.82% stake in the company. Shares short for MNMD as of 1719532800 were 7383486 with a Short Ratio of 5.19, compared to 1717113600 on 6381052. Therefore, it implies a Short% of Shares Outstanding of 7383486 and a Short% of Float of 10.280000000000001.
Earnings Estimates
The stock of Mind Medicine Inc (MNMD) is currently being evaluated by 8.0 analysts who are actively contributing to its market rating.On average, analysts expect EPS of -$0.33 for the current quarter, with a high estimate of -$0.27 and a low estimate of -$0.46, while EPS last year was -$0.76. The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.28 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.66 and -$2.2 for the fiscal current year, implying an average EPS of -$1.92. EPS for the following year is -$1.51, with 7.0 analysts recommending between -$1.36 and -$1.82.
